AI-Designed Drug Rentosertib Shows Reversal on Six Aging Clocks

Insilico Medicine's AI-designed drug rentosertib, originally built to treat lung fibrosis, showed reduced biological age across six independent proteomic "aging clocks" in a 42-patient trial, with lung function also improving against placebo. The molecule, generated end-to-end by artificial intelligence, has now advanced to a 320-patient Phase III trial, and researchers frame the results as a template for engineering treatments that target aging itself rather than only disease. The pursuit of technology to slow or reverse the body's mortal limits reflects a widening human effort to postpone death through scientific means rather than accept it as part of the created order.